Interaction Checker

Tretinoin interactions

Tretinoin (Retin-A, Renova, Altreno), a retinoid has 70 documented interactions across the FDA labels and fact sheets we index: 66 major, 4 moderate, 0 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Major interactions (66)

  • AdapaleneretinoidMajor

    Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (Tretinoin label, Contraindications)

  • AmiodaroneantiarrhythmicMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • AprepitantCYP3A4 inhibitorMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • ArmodafinilCNS stimulantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • BeclomethasonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • BetamethasonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • BosentanCYP3A4 inducerMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • BudesonidecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • Budesonide and formoterolcorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • CarbamazepineanticonvulsantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • CenobamateanticonvulsantMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • CimetidineH2 blockerMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Clarithromycinmacrolide antibioticMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • ClobazambenzodiazepineMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • ClobetasolcorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • CyclosporineimmunosuppressantMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Deferasiroxiron supplementMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • DesonidecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • DexamethasonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • Diltiazemcalcium channel blockerMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • DronedaroneantiarrhythmicMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Erythromycinmacrolide antibioticMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • EslicarbazepineanticonvulsantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • EverolimusimmunosuppressantMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Fluconazoleazole antifungalMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • FludrocortisonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • FluocinonidecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • FluticasonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • Fluticasone and salmeterolcorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • GriseofulvinantifungalMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • HalobetasolcorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • HydrocortisonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • HydroxyureaantimetaboliteMajor

    • Leukocytosis: Consider administering cytoreductive chemotherapy (including an anthracycline if not contraindicated or hydroxyurea) with tretinoin capsules in the setting of leukocytosis, as clinically indicated. (Tretinoin label, Warnings and precautions)

  • ImatinibCYP3A4 inhibitorMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • IsoniazidantibioticMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • IsotretinoinretinoidMajor

    Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (Tretinoin label, Contraindications)

  • Itraconazoleazole antifungalMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • IvacaftorCYP3A4 inhibitorMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Ketoconazoleazole antifungalMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • MethylprednisolonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • Minocyclinetetracycline antibioticMajor

    Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (Minocycline label, Warnings and precautions)

  • Mirabegronbeta-adrenergic agonistMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • ModafinilCNS stimulantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • MometasonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • Nirmatrelvir and ritonavirantiviralMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • OxcarbazepineanticonvulsantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • PalbociclibCYP3A4 inhibitorMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • PerampanelanticonvulsantMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • PhenobarbitalbarbiturateMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • Phentermine and topiramateCNS stimulantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • PhenytoinanticonvulsantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • Posaconazoleazole antifungalMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • PrednisolonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • PrednisonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • PrimidoneanticonvulsantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • RanolazineQT-prolonging drugMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • RifampinantibioticMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • RitonavirantiretroviralMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Suvorexantsedative-hypnoticMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Tetracyclinetetracycline antibioticMajor

    Concomitant use of isotretinoin and tetracycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. (Tetracycline label, Warnings)

  • Ticagrelorantiplatelet agentMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • TopiramateanticonvulsantMajor

    Avoid concomitant use with strong CYP3A inducers if possible. (Tretinoin label, Drug interactions)

  • Tranexamic acidantifibrinolyticMajor

    Avoid concomitant use of tretinoin capsules and anti-fibrinolytic agents, such as tranexamic acid, aminocaproic acid or aprotinin [see Drug Interactions ( 7.4 )] . (Tretinoin label, Warnings and precautions)

  • TriamcinolonecorticosteroidMajor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (Tretinoin label, Boxed warning)

  • Verapamilcalcium channel blockerMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

  • Voriconazoleazole antifungalMajor

    • Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin label, Drug interactions)

Moderate interactions (4)

  • Doxycyclinetetracycline antibioticModerate

    The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (Tretinoin label, Warnings and precautions)

  • Elexacaftor, tezacaftor, and ivacaftorModerate

    Patients with elevated vitamin A levels may be at increased risk. (Elexacaftor, tezacaftor, and ivacaftor label, Warnings and precautions)

  • MethotrexateimmunosuppressantModerate

    Monitor patients receiving XATMEP with other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) for possible signs of hepatotoxicity. (Methotrexate label, Drug interactions)

  • OrlistatModerate

    The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (Orlistat label, Drug interactions)

Check Tretinoin against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.